当前位置： SCI文献检索 > THROMBOSIS RESEARCH期刊下所有文献 > Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome.

Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome.

Abstract：

BACKGROUND:HELLP (Hemolysis, elevated liver enzymes and low platelets) syndrome is a severe and acute pregnancy-related disorder that occurs in approximately 2.5 per 1000 deliveries and represents a major cause of maternal and perinatal morbidity and mortality. This syndrome has been suggested to be a microangiopathy and delivery is the only effective treatment. OBJECTIVES:The aim of this study was to investigate the pathophysiology of HELLP syndrome by simultaneously exploring complement, haemostasis, autoimmunity and inflammation in relation to the clinical outcome. METHODS:We investigated 19 HELLP patients at the time of diagnosis and 3 months after delivery, for complement function, haemostasis and inflammation with immunoenzymatic methods. Complement-related gene variants were also analyzed by next generation sequencing and multiplex ligation-dependent probe amplification. Nineteen age-matched healthy pregnant women served as controls. RESULTS:At diagnosis, HELLP patients, compared to controls, showed significantly higher plasma levels of SC5b-9 (median 710 ng/ml [range 216-1499] vs 253 ng/ml [19-371], P < 0.0001) and of C5a (20.8 ng/ml [5.6-27.5] vs 12.7 ng/ml [3.2-24.6]; P = 0.004), which decreased three months after delivery (SC5b9: 190 ng/ml [83-446] vs 160 ng/ml [107-219]; C5a: 9.28 ng/ml [2.3-21.6] vs 10.7 ng/ml [2.5-21.2]). A significantly higher frequency of genetic variants involving complement regulatory genes was also observed (52.6% vs 15.8%; P = 0.016). Moreover, at HELLP diagnosis, patients showed increased coagulation markers (fragment F1 + 2 and D-dimer; P = 0.0001) while both patients and controls had high thrombin-generation potential that decreased after delivery. CONCLUSIONS:In the pathophysiology of HELLP syndrome, complement dysregulation, in addition to coagulation activation, is involved and may represent a potential target for treatment with the aim of delaying delivery.

journal_name

Thromb Res

journal_title

Thrombosis research

authors

Bazzan M,Todros T,Tedeschi S,Ardissino G,Cardaropoli S,Stella S,Montaruli B,Marchese C,Roccatello D,Cugno M

doi

10.1016/j.thromres.2020.08.038

subject

Has Abstract

pub_date

2020-12-01 00:00:00

pages

167-174

eissn

0049-3848

issn

1879-2472

pii

S0049-3848(20)30486-2

journal_volume

196

pub_type

杂志文章

在线工具

Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome.